NSE filing, NSE: CESC. Summary written from the filing by ALFA Finder's alert engine.
CESC Ltd: key numbers
- Share price
- ₹124.63
- Market cap
- ₹16,521 Cr
- Revenue (annual)
- ₹18,570 Cr
- Net profit (annual)
- ₹1,542 Cr
- P/E (TTM)
- 10.7×Sector 21.3×
- Promoter holding
- 52.11%+0.00% QoQ
- FII holding
- 11.49%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from CESC Ltd
All →CESC Acquisition Worth ₹4,859 Cr
CESC revised the completion timeline for acquiring six ReNew renewable entities to November 21, 2026. The deal covers 1.4 GWp capacity at Rs 4,859 crore enterprise value.
- Value
- ₹4,859 Cr
- operational renewable power capacity acquired
- 1411.48 MWp
CESC Board Meeting Date
CESC Ltd scheduled its Board Meeting for 5 Nov 2026 to consider Q2/H1 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.
CESC Other Announcement
CESC Ltd has submitted its shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.
CESC Other Announcement
This is a routine compliance filing submitting the quarterly certificate under Regulation 74(5) regarding dematerialization activity for the period ended September 30, 2026.
CESC Bags ₹40 Cr Order from Prism Johnson Limited
CESC's subsidiary Purvah Green Power signed a 25-year PPA with Prism Johnson for a 49.5 MW wind project. Prism Johnson will invest Rs. 40 Crore for a 26.5% stake.
- Value
- ₹40.00 Cr
- From
- Prism Johnson Limited (PJL)
- Execution
- 25 years
- wind power project
- 49.5 MW
CESC Debt & Borrowing: ₹150 Cr
CESC Limited fully redeemed Commercial Paper worth ₹150 Crore on September 23, 2026. This disclosure confirms the company's repayment of its debt obligations.
- Value
- ₹150.0 Cr
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr